drugset / Trial / NCT01088932

Multiple Dose Safety Study of SRX246 Capsules in Healthy Volunteers

NCT01088932 ↗

Phase 1 Completed 24 enrolled Azevan Pharmaceuticals
RandomizedSingle-groupQuadruple-blind

Summary

This is a multiple dose clinical study to be conducted with SRX246 capsules to determine the safety, tolerability and pharmacokinetics of the drug over a 14 day dosing period.

Timeline

Start
2010-03
Primary completion
2010-06
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject SRX246 Small molecule — Oral

Indications

No indication recorded.